Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Name
Dutt-2011-Inhibitor-sensitive.pdf
Size
559.37 KB
Format
Adobe PDF
Checksum (MD5)
5f1f1bb6d93ff2b5755da24a13b4ea08
Author(s)
Dutt, Amit
Ramos, Alex H.
Hammerman, Peter S.
Mermel, Craig H.
Cho, Jeonghee
Sharifnia, Tanaz
Chande, Ajit
Tanaka, Kumiko Elisa
Stransky, Nicolas
Greulich, Heidi
Date Issued
June 2011
Journal
PLoS ONE
Publisher
Public Library of Science
Citation
Dutt, Amit et al. “Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer.” Ed. Ming You. PLoS ONE 6 (2011): e20351.
Version
Final published version
Abstract
Background
Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in squamous cell lung carcinoma.
Methodology/Principal Findings
Using SNP array analysis, we found that a region of chromosome segment 8p11-12 containing three genes–WHSC1L1, LETM2, and FGFR1–is amplified in 3% of lung adenocarcinomas and 21% of squamous cell lung carcinomas. Furthermore, we demonstrated that a non-small cell lung carcinoma cell line harboring focal amplification of FGFR1 is dependent on FGFR1 activity for cell growth, as treatment of this cell line either with FGFR1-specific shRNAs or with FGFR small molecule enzymatic inhibitors leads to cell growth inhibition.
Conclusions/Significance
These studies show that FGFR1 amplification is common in squamous cell lung cancer, and that FGFR1 may represent a promising therapeutic target in non-small cell lung cancer.
MIT Department
Whitaker College of Health Sciences and Technology
Broad Institute of MIT and Harvard
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1371/journal.pone.0020351
